2024年9月12日,罗氏(Roche)在2024年欧洲糖尿病研究协会(EASD)年会上公布了其口服胰高血糖素样肽-1(GLP-1)受体激动剂CT-996的1期临床试验结果。最新结果显示,CT-996在未患有2型糖尿病的肥胖人群中,在4周内将参与者体重减轻7.3%(约7公斤)。基于这一积极结果,该公司计划在2025年启动2期临床试验。
▲CT-996的减重效果(图片来源:参考资料[1])
CT-996是一款每日一次的口服GLP-1受体小分子激动剂。罗氏在去年12月与Carmot Therapeutics达成合并协议,斥资约31亿美元收购了Carmot公司,囊获包括CT-996在内的多款处于临床开发阶段的皮下和口服肠促胰岛素疗法。
参考资料:
[1] Safety, Pharmacokinetics, and Pharmacodynamics of CT-996, an Oral Small-Molecule, Signal-Biased GLP-1 Receptor Agonist Over 4 Weeks in Adults With Obesity. Retrieved September 11, 2024, from https://medically.roche.com/global/en/metabolism/easd-2024/medical-material/EASD-2024-presentation-chakravarthy-ct-996-an-oral-small-molecule-signal-biased-pdf.html
[2] Roche says its Carmot-acquired obesity pill is effective in early study. Retrieved September 11, 2024, from https://endpts.com/roche-says-its-carmot-acquired-obesity-pill-is-effective-in-early-study/